Immunocore Announces Proposed Convertible Senior Notes Offering

Read the rest here:
Immunocore Announces Proposed Convertible Senior Notes Offering

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.

Excerpt from:
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company.

See original here:
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the treatment of invasive candidiasis in adults.

See original here:
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247.

Follow this link:
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and...

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong —

The rest is here:
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

PRESS RELEASE – INSIDE INFORMATION

Read more from the original source:
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform

Visit link:
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

See more here:
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

View post:
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the...

hBcl2 overexpression in BMSCs enhances resistance to myelin debris-induced apoptosis and facilitates ...  Nature.com

Read the original post:
hBcl2 overexpression in BMSCs enhances resistance to myelin debris-induced apoptosis and facilitates ... - Nature.com

Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric ...  Nature.com

Read the original here:
Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric ... - Nature.com

1st-of-its-kind therapy blocks immune attack after stem-cell transplant  Livescience.com

Continue reading here:
1st-of-its-kind therapy blocks immune attack after stem-cell transplant - Livescience.com

Implications of stress-induced gene expression for hematopoietic stem cell aging studies  Nature.com

More:
Implications of stress-induced gene expression for hematopoietic stem cell aging studies - Nature.com

LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley  The Morning Call

Here is the original post:
LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley - The Morning Call

Fast Five Quiz: Chronic GVHD Risk Factors and Prevention  Medscape Reference

View original post here:
Fast Five Quiz: Chronic GVHD Risk Factors and Prevention - Medscape Reference

Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates?  BioSpace

Originally posted here:
Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates? - BioSpace

Herbosa: Clinic under probe after skin treatments linked to womans death  Philstar.com

See the article here:
Herbosa: Clinic under probe after skin treatments linked to womans death - Philstar.com

DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021, July 11, 2022 and March 31, 2023 (the “Credit Agreement”).

Here is the original post:
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course.

Original post:
Kane Biotech Announces Special Meeting of Shareholders